ARTICLE | Finance
Asceneuron's clinical path
Why Sofinnova Partners led preclinical tau biology play Asceneuron's A round
October 5, 2015 7:00 AM UTC
Investors pulled the trigger on a CHF30 million ($30.7 million) A round for preclinical neurology play Asceneuron S.A. last week thanks to a combination of in vivoproof-of-concept data and advances in neurological imaging technologies that the biotech could use in clinical trials.
Sofinnova Partners led the round, with participation from fellow new investors SR One, Kurma Partners and Johnson & Johnson Innovation-JJDC Inc., plus existing investor MS Ventures, Merck Serono S.A.'s venture arm...